Trials / Completed
CompletedNCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Conditions
- Cervical Cancer
- Gastric Cancer
- Stomach Cancer
- Gastroesophageal Junction Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Uveal Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- MSI
- Non-small Cell Lung Cancer
- NSCLC
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- RCC
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Mismatch Repair Deficiency
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCAGN02390 | Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD. |
Timeline
- Start date
- 2018-09-24
- Primary completion
- 2021-08-18
- Completion
- 2021-08-18
- First posted
- 2018-08-29
- Last updated
- 2021-11-15
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03652077. Inclusion in this directory is not an endorsement.